Ropinirole for the treatment of early Parkinson disease: A 12-month experience

K. D. Sethi, C. F. O'Brien, J. P. Hammerstad, C. H. Adler, T. L. Davis, R. L. Taylor, J. Sanchez-Ramos, J. M. Bertoni, R. A. Hauser

Research output: Contribution to journalArticle

82 Scopus citations

Abstract

Objective: To evaluate ropinirole hydrochloride as dopaminergic monotherapy in patients with early Parkinson disease. Design: A 6-month extension of a double-blind, placebo-controlled study. Setting: Ambulatory care at 22 different sites in the United States. Patients: Patients who successfully completed the initial 6-month study could enter the 6-month extension study (ropinirole, n = 70; placebo, n = 77). Intervention: Use of ropinirole or placebo therapy. Main Outcome Measures: The efficacy variables were the number of patients who successfully completed the 12-month study and did not require supplemental levodopa, the number of patients requiring supplemental levodopa, and the proportion of patients having an insufficient therapeutic response. Results: Significantly fewer ropinirole-treated patients met criteria for insufficient therapeutic response (23 [19.8%] of 116) or required the initiation of levodopa therapy (22 [19%] of 116) compared with placebo-treated patients (60 [48%] of 125 patients for insufficient therapeutic response; 57 [45.6%] of 125 patients for additional levodopa). Significantly more ropinirole-treated patients (51 [44.0%] of 116) successfully completed the 12-month study and did not require supplemental levodopa compared with placebo-treated patients (28 [22.4%] of 125). The incidence of adverse experiences and patient withdrawals was low. Conclusion: Ropinirole was effective and well tolerated as monotherapy for 12 months in patients with early Parkinson disease.

Original languageEnglish (US)
Pages (from-to)1211-1216
Number of pages6
JournalArchives of Neurology
Volume55
Issue number9
DOIs
StatePublished - Sep 1 1998

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Ropinirole for the treatment of early Parkinson disease: A 12-month experience'. Together they form a unique fingerprint.

  • Cite this

    Sethi, K. D., O'Brien, C. F., Hammerstad, J. P., Adler, C. H., Davis, T. L., Taylor, R. L., Sanchez-Ramos, J., Bertoni, J. M., & Hauser, R. A. (1998). Ropinirole for the treatment of early Parkinson disease: A 12-month experience. Archives of Neurology, 55(9), 1211-1216. https://doi.org/10.1001/archneur.55.9.1211